Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250147003> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4250147003 endingPage "4763" @default.
- W4250147003 startingPage "4763" @default.
- W4250147003 abstract "4763 Background: Samuels et al (1980 Proc ASCO 21 abst 415) observed 4 of 5 bulky seminomas achieved durable CR to single agent cisplatin and Oliver 1984 Proc ASCO 3. Abst 636) reported 9 of 10 durable responses. Carboplatin proved less effective and in randomised trials involving 361 patients relapse free survival was 71% with Carbo and 91% with cisplatin-based combination. Prompted by successful dose escalation of carboplatin in ovarian cancer, the initial phase 1 study that preceded the UK randomised trial was reopened and dosage escalation to AUC 8 and then 10 was undertaken. This abstract updates this study with more prolonged follow up of the previous cases and new information on the higher dosages. Methods: Initially patients received 450mg/m2 and subsequently the dose was increased to AUC 7, 8 and 10. The treatment was repeated q21 when possible and if delayed because of toxicity blood counts were repeated every 24 hours. Results: A total of 49 metastatic seminoma patients have been treated between 1983 and 2003. 79% of 19 receiving 450mg/m2, 88% of 17 receiving AUC 7 or 8 and 92% of 12 receiving AUC 10 are relapse free. As a pilot study 7 patients with a variety of metastatic germ cell cancers have had PET scan performed before and at 72 hours after treatment. 3 achieved CR, 3 had greater than 40% response and 1 after progressing after single agent carboplatin was in complete remission after one course of BEP. Conclusion: With late events increasingly a problem with more prolonged follow up of testis cancer, minimizing treatment toxicity and finding a fast track approach to proving safety is an increasing need. The data presented demonstrates the potential of early PET scan as a surrogate marker to facilitate assessment of response and could have accelerated the phase 1/2 study reported. No significant financial relationships to disclose." @default.
- W4250147003 created "2022-05-12" @default.
- W4250147003 creator A5018577229 @default.
- W4250147003 creator A5023611167 @default.
- W4250147003 creator A5039368541 @default.
- W4250147003 creator A5042414917 @default.
- W4250147003 date "2004-07-15" @default.
- W4250147003 modified "2023-09-24" @default.
- W4250147003 title "20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response?" @default.
- W4250147003 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4763" @default.
- W4250147003 hasPublicationYear "2004" @default.
- W4250147003 type Work @default.
- W4250147003 citedByCount "1" @default.
- W4250147003 crossrefType "journal-article" @default.
- W4250147003 hasAuthorship W4250147003A5018577229 @default.
- W4250147003 hasAuthorship W4250147003A5023611167 @default.
- W4250147003 hasAuthorship W4250147003A5039368541 @default.
- W4250147003 hasAuthorship W4250147003A5042414917 @default.
- W4250147003 hasConcept C126322002 @default.
- W4250147003 hasConcept C126838900 @default.
- W4250147003 hasConcept C143998085 @default.
- W4250147003 hasConcept C2776694085 @default.
- W4250147003 hasConcept C2778074268 @default.
- W4250147003 hasConcept C2778239845 @default.
- W4250147003 hasConcept C2781451048 @default.
- W4250147003 hasConcept C2989005 @default.
- W4250147003 hasConcept C31760486 @default.
- W4250147003 hasConcept C71924100 @default.
- W4250147003 hasConceptScore W4250147003C126322002 @default.
- W4250147003 hasConceptScore W4250147003C126838900 @default.
- W4250147003 hasConceptScore W4250147003C143998085 @default.
- W4250147003 hasConceptScore W4250147003C2776694085 @default.
- W4250147003 hasConceptScore W4250147003C2778074268 @default.
- W4250147003 hasConceptScore W4250147003C2778239845 @default.
- W4250147003 hasConceptScore W4250147003C2781451048 @default.
- W4250147003 hasConceptScore W4250147003C2989005 @default.
- W4250147003 hasConceptScore W4250147003C31760486 @default.
- W4250147003 hasConceptScore W4250147003C71924100 @default.
- W4250147003 hasIssue "14_suppl" @default.
- W4250147003 hasLocation W42501470031 @default.
- W4250147003 hasOpenAccess W4250147003 @default.
- W4250147003 hasPrimaryLocation W42501470031 @default.
- W4250147003 hasRelatedWork W1481820868 @default.
- W4250147003 hasRelatedWork W151172257 @default.
- W4250147003 hasRelatedWork W1978346427 @default.
- W4250147003 hasRelatedWork W2053644560 @default.
- W4250147003 hasRelatedWork W2074080783 @default.
- W4250147003 hasRelatedWork W2471989939 @default.
- W4250147003 hasRelatedWork W2510670462 @default.
- W4250147003 hasRelatedWork W2530877275 @default.
- W4250147003 hasRelatedWork W3206704704 @default.
- W4250147003 hasRelatedWork W4226023057 @default.
- W4250147003 hasVolume "22" @default.
- W4250147003 isParatext "false" @default.
- W4250147003 isRetracted "false" @default.
- W4250147003 workType "article" @default.